The Program Committee of the AUA has accepted the Theralase®'s abstract titled: ' Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive ...

TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...

Did you know that one in two young people in Canada aren't getting the mental health support they need? The growing mental health crisis among young people in our communities demands action and that's ...

Obsidian Security, the pioneer in Software as a Service (SaaS) security, today released its inaugural 2025 SaaS Security Threat Report, revealing an unprecedented 300% year-over-year increase in SaaS ...

for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

therapy for patients with BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) (). In an international study involving 299 patients with BCG-unresponsive NMIBC across 10 centers, 204 ...

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Overactive bladder (OAB) is typically not painful, but it can cause significant discomfort and a sudden, strong urge to urinate. OAB causes sudden, involuntary contractions of the bladder muscle ...

The president, who has assailed California’s leaders over wildfires, issued the directive in an executive order that was dated Friday but released on Sunday. By Zach Montague and Catrin Einhorn ...

“Our long-standing commitment to the genitourinary cancer community has been foundational in our mission to transform the treatment landscapes for patients with bladder and prostate cancers ...